Oncology and Hematology - Global Oncology Academy

Episodes 97-112 of 125

Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
MinuteCE®
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
1.00 program credit
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
CME/CE
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
0.50 credits
- Guy Young, MD
0.50 credits
Which TNBC Patients Are Eligible for ADCs?
Which TNBC Patients Are Eligible for ADCs?
MinuteCE®
Which TNBC Patients Are Eligible for ADCs?
1.00 program credit
- Sara A. Hurvitz, MD, FACP
1.00 program credit
What Is the Future of ADCs in Metastatic TNBC?
What Is the Future of ADCs in Metastatic TNBC?
MinuteCE®
What Is the Future of ADCs in Metastatic TNBC?
1.00 program credit
- Sara A. Hurvitz, MD, FACP
- Sara M. Tolaney MD, MPH
1.00 program credit
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
MinuteCE®
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
1.00 program credit
- Sara A. Hurvitz, MD, FACP
1.00 program credit
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
MinuteCE®
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
1.00 program credit
- Sara A. Hurvitz, MD, FACP
1.00 program credit
ADC Targets: Does Positivity Really Matter?
ADC Targets: Does Positivity Really Matter?
MinuteCE®
ADC Targets: Does Positivity Really Matter?
1.00 program credit
- Sara M. Tolaney MD, MPH
1.00 program credit
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
MinuteCE®
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
1.00 program credit
- Sara A. Hurvitz, MD, FACP
- Sara M. Tolaney MD, MPH
1.00 program credit
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
MinuteCE®
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
1.00 program credit
- Sara M. Tolaney MD, MPH
1.00 program credit
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
MinuteCE®
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
1.00 program credit
- Sara M. Tolaney MD, MPH
1.00 program credit
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
MinuteCE®
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
1.00 program credit
- Sara M. Tolaney MD, MPH
1.00 program credit
MinuteCE®
Triple-Negative Breast Cancer (TNBC): Choosing the Right ADC for the Right Patient
1.00 credit 9 episodes
- Sara A. Hurvitz, MD, FACP
- Sara M. Tolaney MD, MPH
1.00 credit 9 episodes
A Changing Approach to TNBC Management: Patients as Partners in Care
A Changing Approach to TNBC Management: Patients as Partners in Care
CME/CE
A Changing Approach to TNBC Management: Patients as Partners in Care
1.00 credit
- Tiffany Traina, MD, FASCO
- Gregory Vidal, MD, PhD
- Stephanie Walker, RN
1.00 credit
Antibody-Drug Conjugates in FL
Antibody-Drug Conjugates in FL
MinuteCE®
Antibody-Drug Conjugates in FL
1.00 program credit
- Matthew J. Matasar, MD
- Kami Maddocks, MD
1.00 program credit
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
MinuteCE®
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
1.00 program credit
- Kami Maddocks, MD
- Matthew J. Matasar, MD
1.00 program credit
Patient Selection for ADCs in First-Line DLBCL
Patient Selection for ADCs in First-Line DLBCL
MinuteCE®
Patient Selection for ADCs in First-Line DLBCL
1.00 program credit
- John P. Leonard, MD
- Sarah Rutherford, MD
1.00 program credit

7/7